An intensive, structured, mobile devices-based healthcare intervention to optimize the lipid-lowering therapy improves lipid control after an acute coronary syndrome

Despite the evidence, lipid-lowering treatment (LLT) in secondary prevention remains insufficient, and a low percentage of patients achieve the recommended LDL cholesterol (LDLc) levels by the guidelines. We aimed to evaluate the efficacy of an intensive, mobile devices-based healthcare lipid-loweri...

Descripción completa

Detalles Bibliográficos
Autores: Ruiz Bustillo, Sonia|||0000-0002-6074-914X, Badosa, Neus|||0000-0003-4960-8634, Cabrera-Aguilera, Ignacio|||0000-0003-1060-4601, Ivern, Consol, Llagostera-Martín, Marc|||0000-0002-6211-7453, Mojón, Diana, Vicente, Miren, Ribas Barquet, Núria|||0000-0003-1492-5285, Recasens, Lluis, Martí-Almor, Julio|||0000-0001-9927-1190, Cladellas Capdevila, Mercè|||0000-0001-8537-6012, Farré, Núria|||0000-0003-3110-6572
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:282974
Acceso en línea:https://ddd.uab.cat/record/282974
https://dx.doi.org/urn:doi:10.3389/fcvm.2022.916031
Access Level:acceso abierto
Palabra clave:Cardiovascular risk factors
Ischemic heart disease
Lipid-lowering therapy
Mobile devices-based healthcare
Secondary prevention
Descripción
Sumario:Despite the evidence, lipid-lowering treatment (LLT) in secondary prevention remains insufficient, and a low percentage of patients achieve the recommended LDL cholesterol (LDLc) levels by the guidelines. We aimed to evaluate the efficacy of an intensive, mobile devices-based healthcare lipid-lowering intervention after hospital discharge in patients hospitalized for acute coronary syndrome (ACS). Ambiespective register in which a mobile devices-based healthcare intervention including periodic follow-up, serial lipid level controls, and optimization of lipid-lowering therapy, if appropriate, was assessed in terms of serum lipid-level control at 12 weeks after discharge. A total of 497 patients, of which 462 (93%) correctly adhered to the optimization protocol, were included in the analysis. At the end of the optimization period, 327 (70.7%) patients had LDLc levels ≤ 70 mg/dL. 40% of patients in the LDLc ≤ 70 mg/dL group were upgraded to very-high intensity lipid-lowering ability therapy vs. 60.7% in the LDLc.

Similares en LA Referencia